Today's pre-market stock movers: AZN, NVS, NKLA, CVX and more

- $Luna Innovations(LUNA.US)$ +8.55% (acquires LIOS Sensing from NKT A/S' NKT Photonics for 20 million in cash; divested Luna Labs for $21 mln)

- $Clene(CLNN.US)$ +3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference)

- $AstraZeneca(AZN.US)$ +2.3% ( AstraZeneca and $Merck & Co(MRK.US)$ 's Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer)

- $Ginkgo Bioworks(DNA.US)$ +1.9% (to acquire Swiss-based strain development and optimization company FGen AG)

- $Novartis AG(NVS.US)$ +1.7% (reports new data reinforcing the benefit of Zolgensma)

- $Flora Growth(FLGC.US)$ +1.2% (has signed a distribution agreement with Israel-based DNO Group)

- $Ecolab(ECL.US)$ +1% (announced its intent to repurchase $500 million of its shares in 2022)

• $Deutsche Bank(DB.US)$ +9% (upgraded to Hold from Sell at Berenberg)

• $Nokia Oyj(NOK.US)$ +5.4% (upgraded to Outperform from Mkt Perform at Raymond James)

• $Fortive(FTV.US)$ +1.4% (upgraded to Overweight from Equal Weight at Barclays)

- $Natera(NTRA.US)$ -6.3% (executives to take compensation packages in stock instead of salary)

- $Nikola(NKLA.US)$ -3.7% (files for 17,025,590 share common stock offering by selling shareholder)

- $Sanofi(SNY.US)$ -2% (provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer; AMEERA-3 trial did not meet primary endpoint of improving progression-free survival)

- $Velodyne Lidar(VLDR.US)$ -0.9% (announces change to Board of Directors and provides update on stock ownership)

- $Chevron(CVX.US)$ -3% (downgraded to Equal-Weight from Overweight at Morgan Stanley)

- $Northern Oil & Gas(NOG.US)$ -2.1% (downgraded to Equal Weight from Overweight at Wells Fargo)

- $Occidental Petroleum(OXY.US)$ -2.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)

- $Vita Coco(COCO.US)$ -1.2% (downgraded to Neutral from Buy at BofA Securities)

- $Tyson Foods(TSN.US)$ -1.2% (downgraded to Market Perform from Outperform at BMO Capital Markets)